Successful treatment of infantile refractory bullous pemphigoid with baricitinib-Reference-Cited by-同舟云学术

Successful treatment of infantile refractory bullous pemphigoid with baricitinib

Published:2024-07-19 Issue: Volume: Page:
ISSN:0004-8380
Container-title:Australasian Journal of Dermatology
language:en
Short-container-title:Aust J Dermatology

Author:

Zhou Weinan¹²³⁴^ORCID,Tan Yidong¹²³⁴^ORCID,Chen Xuanyi¹²³⁴,Zhang Wenqing¹²³⁴^ORCID,Sun Zhe¹²³⁴,Shen Yihang¹²³⁴,Yao Zhirong¹²³⁴^ORCID,Cheng Ruhong¹²³⁴,Gu Yan¹²³⁴

Affiliation:

1. Dermatology Center, Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China

2. Department of Dermatology Shanghai Jiaotong University School of Medicine Shanghai China

3. Institute of Dermatology Shanghai Jiaotong University School of Medicine Shanghai China

4. Department of Allergy, Dermatology Center, Xinhua Hospital Shanghai Jiaotong University School of Medicine Shanghai China

Abstract

AbstractInfantile bullous pemphigoid (BP) is a rare autoantibody‐mediated skin disorder. We report the effective treatment of a 6‐month‐old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses. To our knowledge, this is the first case of baricitinib used in an infant with BP.

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajd.14345

Reference10 articles.

1. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study

2. Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects

3. Incidence and Mortality of Bullous Pemphigoid in France

4. Bullous pemphigoid in infants: characteristics, diagnosis and treatment

5. A Comparison for Type 2 Cytokines and Lesional Inflammatory Infiltrations in Bullous Pemphigoid and Atopic Dermatitis